Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)

DRUG2 trials

Sponsors

Hoffmann-La Roche, Ain Shams University

Conditions

Atopic DermatitisOral Lichen PlanusTumor Necrosis Factor-alpha

Phase 2

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

CompletedNCT02465606

Hoffmann-La RocheAtopic Dermatitis

Start: 2015-07-30End: 2016-05-30Updated: 2020-01-27

Phase 4

Efficacy of Aloe Vera Compared to Corticosteroid in Topical Treatment of Oral Lichen Planus and on Salivary Levels of Tumor Necrosis Factor Alpha

CompletedNCT07792512

Ain Shams UniversityOral Lichen Planus, Tumor Necrosis Factor-alpha

Start: 2022-01-20End: 2025-08-05Updated: 2026-08-28

Related Papers

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

American Journal of Clinical Dermatology2023-05-1760 citations

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

JAMA Dermatology2023-01-11119 citations

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

JAMA Dermatology2020-02-26329 citations